agilon health Inc (AGL) PT Raised to $13 at Benchmark

Benchmark analyst Bill Sutherland raised the price target on agilon health Inc (NYSE: AGL) to $13.00 (from $1.50) while maintaining a Buy rating.

The analyst commented, "We adjust our price target to $13 to reflect this week’s 1:25 reverse stock split and adjustments to our model. Our FY26 AEBITDA estimate is lifted more in line with guidance and our FY27 AEBITDA outlook is reduced to reflect the disappointing MA advance rate that may limit the margin gains achievable through expected company initiatives. Our updated PT of $13 implies 2027E EV/AEBITDA of 5.8x based on expected cash at 12/31/26."

You May Also Be Interested In

• Qualcomm (QCOM) PT Raised to $195 at BofA Securities
• Kroger (KR) PT Lowered to $63 at UBS as Execution Challenges Persist
• Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink